# ETER100 (NCT04523272)

> A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

No report yet. It can be ordered.

- Drugs tested: benmelstobart plus anlotinib
- Indication: first-line advanced renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04523272
- Phase: PHASE3
- Status: UNKNOWN
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Conditions: Advanced Renal Cancer
- Interventions: TQB2450; Anlotinib; Sunitinib
- Enrollment: 528
- Primary outcome: Progression free survival (PFS) evaluated by Independent Review Committee(IRC)

## Indexed commentary on ETER100 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=eter100-nct04523272

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04523272", "email": "<work email>"}; the inbox owner confirms by the emailed link.